Medindia

X

Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2009 Financial Results

Thursday, March 4, 2010 Press Release J E 4
Advertisement


SAN DIEGO, March 3 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it expects to report fourth quarter and full year 2009 financial results after the NASDAQ Global Market closes on Thursday, March 11, 2010. The Company also expects to host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter and full year 2009, as well as provide a corporate update.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 375-5161 for domestic callers and (631) 291-4558 for international callers. Please specify to the operator that you would like to join "Optimer's Earnings Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is a new class of antibiotics with narrow spectrum bactericidal activity targeted at the site of infection. Recently reported positive top-line results from the second Phase 3 trial confirmed the results from the first Phase 3 trial regarding fidaxomicin's safety and efficacy in patients with Clostridium difficile infection. Optimer has also successfully completed two Phase 3 trials with Pruvel(TM), for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts Optimer Pharmaceuticals, Inc. John Prunty, CFO & VP, Finance Christina Donaghy, Corporate Communications Manager 858-909-0736 Porter Novelli Life Sciences Jason I. Spark, Vice President 619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Researchers Pave Way for Tracking of Prostate Moti...
S
Pregis Announces Extension of Exchange Offer